Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294450 · ClinicalTrials.gov registry record · Phase 2
Feasibility Study of a New Fistula Pouching System
A Phase 2 study of Cutaneous Fistula, sponsored by Coloplast A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 7
- Study locations
NCT00294450 is a Phase 2 study of Cutaneous Fistula that has completed, run by Coloplast A/S. The registered enrollment target is 22 participants. The trial reports 7 study locations across 5 states.
The verdict
NCT00294450, a Phase 2 study of Cutaneous Fistula, has completed, sponsored by Coloplast A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this investigation is to carry out a clinical evaluation of a newly developed fistula pouching system's ability to function as a good pouch for fistulas, with the opening on the skin of the stomach or in a wound on the skin of the stomach.
Conditions Studied
Interventions
- DEVICE Fistula Pouching System
Study Locations (7)
Minnesota
- Fairview Southdale Hospital - Edina
- University of Minnesota Medical Center Fairview - Riverside - Minneapolis
- University of Minnesota Medical Center Fairview - Minneapolis
Connecticut
- St. Francis Hospital and Medical Center - Hartford
Florida
- Morton Plant Hospital - Clearwarter
Ohio
- The Cleveland Clinic Foundation - Cleveland
Texas
- Presbyterian Hospital of Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00294450
The ClinicalTrials.gov registry entry for NCT00294450 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Coloplast A/S, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cutaneous Fistula appearing as the primary indexed condition, and to 1 intervention - of which Fistula Pouching System is the first listed.
NCT00294450 reports 7 study locations spanning 5 distinct geographic areas - top geographies include Minnesota, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00294450 about?
NCT00294450 is a clinical study titled "Feasibility Study of a New Fistula Pouching System". The purpose of this investigation is to carry out a clinical evaluation of a newly developed fistula pouching system's ability to function as a good pouch for fistulas, with the opening on the skin of the stomach or in a wound on the skin of the stomach.
What is the current status of trial NCT00294450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-02. Estimated completion is 2007-03.
What conditions does trial NCT00294450 study?
This clinical trial studies the following conditions: Cutaneous Fistula.
What interventions are being tested in trial NCT00294450?
The interventions under investigation include: Fistula Pouching System (DEVICE).
Who is sponsoring clinical trial NCT00294450?
This trial is sponsored by Coloplast A/S, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00294450 being conducted?
This trial has 7 study locations across Connecticut, Florida, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.